US gonorrhoea rates rose by 19% in 2017

Organisation: Position: Deadline Date: Location:

Gonorrhoea infection is the second most commonly reported notifiable condition in the US, and case rates have been increasing since 2009, writes Dr Susan Blank, and Dr Demetre C Daskalakis from the division of disease control, New York City Department of Health and Mental Hygiene and the division of STD prevention, National Centre for HIV, Viral Hepatitis, STD, and TB Prevention, Centres for Disease Control and Prevention, Atlanta in a New England Journal of Medicine perspective.

They write: “In 2017, a total of 555,608 cases of gonorrhoea were reported nationally, the largest number since 1991 and an 18.6% increase over 2016 (see graph). In 2015, the Obama administration deemed Clostridium difficile, carbapenem-resistant Enterobacteriaceae, and Neisseria gonorrhoeae the most urgent infectious public health threats to national security, given the accelerating emergence of antibiotic resistance in these organisms. Though gonorrhoea ranked third on this list, the number of cases of gonorrhoea dwarfs those of the other two infections.

“Worldwide, gonorrhoea cases have persistently affected young adults. Without a concerted global effort to mitigate antibiotic resistance, infected persons (primarily, sexually active young adults, who tend to be otherwise healthy) may require extended hospital stays and additional follow-up visits for an infection that can currently be managed on an outpatient basis. Such a shift could impose a serious burden on health care systems and societal productivity internationally. In the US, this concern is compounded by the fact that for decades, gonorrhoea infections have disproportionately affected black Americans, American Indians and Alaska Natives, Native Hawaiians and other Pacific Islanders, and Hispanic Americans.

“Untreated gonorrhoea infection can have serious health consequences. It is transmitted from an infected person to a partner during sex or from an infected woman to her baby at delivery. Infections are frequently asymptomatic, but they can lead to serious sequelae such as pelvic inflammatory disease, ectopic pregnancy, infertility, destructive arthritis, disseminated infection, and blindness in neonates born through an infected birth canal. In addition, the mucosal inflammation caused by N. gonorrhoeae may facilitate the transmission of HIV between sex partners.

“The Centres for Disease Control and Prevention (CDC) estimates that the annual domestic cost of treating these acute infections and their sequelae is $182.2m (in 2017 dollars). This estimate excludes the cost of gonorrhoea-attributable HIV infections and adverse pregnancy outcomes.

“Controlling gonorrhoea in a population requires many connected activities. It requires access to screening, routine assessment of patients’ sexual practices to guide the identification of anatomical sites requiring specimen collection, laboratory capacity to perform testing, diagnostic technology that can characterize the organism and its antibiotic susceptibility, systems for gathering that information to guide treatment recommendations, and above all, effective and simple antibiotic therapy.

“N. gonorrhoeae is prone to the development of antibiotic resistance, and our ability to monitor antibiotic susceptibility is limited. The advent and increasing adoption of nucleic acid amplification tests (NAATs) has enabled molecular screening of urine as well as of swabs from the vagina, rectum, and oropharynx. These tests for diagnosing gonorrhoea are more reliable and convenient than bacterial cultures and have largely supplanted the use of cultures. However, NAAT technology for N. gonorrhoeae currently does not provide antibiotic-susceptibility information. Culture is required for that purpose, but since it is impractical to perform for every patient, many practices have ceased to stock the correct culture medium for such testing.

“The CDC Gonococcal Isolate Surveillance Programme (GISP) has monitored population-level antibiotic susceptibility and resistance patterns from selected sites throughout the US since the 1980s and has used these data to inform its national treatment recommendations. Since 2015, funds from the national initiative to Combat Antibiotic Resistant Bacteria (CARB) have been used to expand surveillance and laboratory capacity for detecting N. gonorrhoeae and to monitor antibiotic susceptibilities, as well as to respond to any significant changes.2 Previous national monitoring efforts revealed high rates of resistance to penicillin and tetracycline, and these drugs are no longer recommended for gonorrhoea. In 2007, with the emergence of fluoroquinolone-resistant gonorrhoea, the CDC stopped recommending the use of that class of drug as well.

“Thereafter, increasing minimum inhibitory concentrations (MICs) of cefixime identified by GISP, combined with reports of treatment failures with cefixime and other oral cephalosporins, led the CDC to cease recommending the use of cefixime regimens as first-line treatment in the US. Ceftriaxone is now the only reliably effective antibiotic, and the CDC recommends one dual regimen for treating gonorrhoea: intramuscular ceftriaxone with oral azithromycin. The two drugs have different mechanisms of action, which will theoretically slow the emergence and spread of gonorrhoea resistance to cephalosporins.

“In the past several years, GISP data have shown increases in the number of specimens with elevated azithromycin MICs, but almost no increase in the number of specimens with elevated ceftriaxone MICs or in the extent of elevation of those MICs. Certain regions of the world have reported gonorrhoea cases with resistance to third-generation cephalosporins and macrolides, the mainstays of treatment. It is unclear how to treat such cases, and if they spread more widely, treating gonorrhoea will become substantially more difficult. Fortunately, in the United States in 2017, all isolates with elevated azithromycin MICs were susceptible to ceftriaxone, and no treatment failures were reported; these findings suggest that the threat of untreatable gonorrhoea in this country has been curtailed for now.

“Nevertheless, as the history of this organism has proven, progression of resistance of N. gonorrhoeae is an ever-present concern, and we are facing the real danger of multidrug-resistant, nearly untreatable gonorrhoea. There is still no effective preventive vaccine against this organism to assist us with disease control. To avoid untreatable cases of this high-incidence infection, we need to advance diagnostic technology and develop treatments with different mechanisms of action. Development of new and effective treatments is also an urgent matter of health equity, given that minority racial or ethnic groups are overrepresented among patients with gonorrhoea in the US and that men who have sex with men and young people are also at the leading edge of increased gonorrhoea incidence.

“Studies like the one reported on by Taylor et al. in this issue (pages 1835–45) are a step forward in the quest to identify new antimicrobial options for gonorrhoea treatment. Given the challenges in clinical follow-up in this patient population, the single-dose regimen is promising. Though the study was small, the efficacy shown is encouraging, and zoliflodacin has the potential to be an effective antibiotic for treating gonorrhoea, though the limited activity observed in key anatomical sites of infection such as the pharynx will need to be better defined.

“In parallel with ongoing work to develop and approve new drugs, we need to develop point-of-care molecular diagnostics that permit rapid diagnosis of gonorrhoea with real-time assessment of antimicrobial susceptibility in order to allow targeted therapy rather than empirical treatment that may be inadequate in the context of increasing antibiotic resistance.

“With more dedicated research on sexually transmitted infections to advance biomedical innovation and develop better diagnostics, therapeutics, and even vaccines, we may be able to avoid the advent of gonorrhoea that is either treatable only with expensive intravenous or intramuscular agents or entirely untreatable. Meanwhile, additional support for the public health infrastructure required for the surveillance, prevention, and treatment of sexually transmitted infections will be critical.”

Authors
Dr Susan Blank, and Dr Demetre C Daskalakis

New England Journal of Medicine perspective

Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.